

Public health impact of introducing adjuvanted recombinant zoster vaccine into the vaccination programme in the UK



Hunjan M¹, Curran D², Marijam A², Schamroth J¹, Vekria Y¹, Giannelos N²
¹GSK, London, UK; ²GSK, Wavre, Belgium



EE624


METHODS

The analyses were conducted utilising a multi-cohort **static Markov model** in cohorts of individuals **65 YOA** and **70 YOA** projected for 2023, using a lifetime perspective.⁵

Vaccine efficacy data for RZV and ZVL are derived from published studies.⁶⁻⁹


Uptake of ZVL and the **first dose of RZV** is assumed to be **40%** and **60%**, respectively.[#]

Compliance for the **second dose of RZV** is assumed to be **50%**.




The objective of this study was to **predict the public health impact** of introducing **RZV** into the **UK immunisation programme** for people **65 YOA** and **70 YOA**.


RZV vaccination resulted in fewer HZ and general practitioner (GP) appointments **compared to no vaccination over the subjects' lifetime**.




RZV vaccination resulted in fewer postherpetic neuralgia (PHN) and hospital admissions **compared to no vaccination over the subjects' lifetime**.



RZV vaccination reduced HZ cases and GP appointments in 70 YOA over 5 years **compared to ZVL vaccination**.



RZV vaccination reduced PHN cases and hospital admissions in 70 YOA over 5 years **compared to ZVL vaccination**.



RESULTS

A higher number of events were avoided in the 65 YOA cohort compared with the 70 YOA individuals.

There was a **reduction** in the number of **HZ cases**, **PHN cases** and **healthcare resource utilisation** in the **70 YOA** cohort after 5 years of vaccination **with RZV**, compared with ZVL vaccination.

CONCLUSIONS

RZV vaccination resulted in **lower numbers of HZ and PHN cases** and **fewer GP appointments and hospital admissions compared with ZVL**, over a 5-year period, and when considering a lifetime perspective.

Introduction of **RZV** into the **national immunisation programme** would **reduce the healthcare burden due to shingles** and associated healthcare resource utilisation, already within the first 5 years of implementation.

[#] Based on approximate cumulative uptake of ZVL in the UK NIP; uptake of RZV is expected to be higher